Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally ...

Reports

4

Domains carrying it

4

First reported

24 August 2026

Latest report

25 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 24 August 2026Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally ...gsk.com
2. 25 August 2026FDA puts GSK's Jemperli on priority review in locally advanced rectal cancerallsci.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• US FDA approves Replimune's skin cancer drug15 reports · 14 domains · 10 August 2026
• FDA Grants Accelerated Approval to a New Breast Cancer Treatment8 reports · 7 domains · 5 September 2026
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer59 reports · 51 domains · 5 September 2026
• FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory ...3 reports · 3 domains · 13 August 2026
• Capricor soars on potential FDA review extension, filing amendments9 reports · 6 domains · 25 August 2026
• FDA Approves Ziihera Regimens in First-Line HER2+ Advanced GEA14 reports · 10 domains · 2 September 2026

◆ Share

◆ Evidence

4 reports · 4 domains

• FDA puts GSK's Jemperli on priority review in locally advanced rectal cancerallsci.com · 25 August 2026
• FDA Accepts Priority Review for Dostarlimab in dMMR/MSI-H Rectal Cancercancernetwork.com · 24 August 2026
• FDA Grants Priority Review to Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Canceronclive.com · 24 August 2026
• Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally ...gsk.com · 24 August 2026